Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...

One of Eli Lilly & Co.’s most highly anticipated experimental medicines helped diabetic patients lose more weight than any ...

A US court has certified a nationwide third party payor class in a lawsuit involving Eli Lilly’s former diabetes drug Actos.

Roche Holding AG expands Nvidia AI GPUs for drug R&D, tops peers with 3,500+ Blackwell chips, see value vs Eli Lilly and ...

GLP-1 therapy Zepbound has become the biggest weight loss drug since its introduction, outpacing Novo Nordisk’s (NYSE:NVO) ...

Eli Lilly & Company (NYSE:LLY) is one of the best growth stocks to buy right now. On March 16, Eli Lilly announced positive ...

While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established ...

HSBC has downgraded Eli Lilly to Reduce, arguing in a note on Tuesday that expectations for the fast-growing obesity drug market have become overly optimistic and that the company’s shares now look ...

Challenges remain in fulfilling the vision of the public-private Lehigh Valley Economic Development Corp. But at its annual ...

Eli Lilly's stock is down this year, and its high valuation may be a big reason why.

Eli Lilly and Co on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12. The company said internal testing detected ...